Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Astrazeneca (AZNCF) EBIT (2016 - 2025)

Historic EBIT for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to $3.0 billion.

  • Astrazeneca's EBIT rose 4626.72% to $3.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $13.7 billion, marking a year-over-year increase of 3738.88%. This contributed to the annual value of $13.7 billion for FY2025, which is 3738.88% up from last year.
  • According to the latest figures from Q4 2025, Astrazeneca's EBIT is $3.0 billion, which was up 4626.72% from $3.6 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's EBIT ranged from a high of $3.7 billion in Q1 2025 and a low of -$1.7 billion during Q3 2021
  • Its 5-year average for EBIT is $1.8 billion, with a median of $2.0 billion in 2023.
  • Its EBIT has fluctuated over the past 5 years, first crashed by 24295.47% in 2021, then soared by 47465.75% in 2022.
  • Astrazeneca's EBIT (Quarter) stood at -$292.0 million in 2021, then skyrocketed by 474.66% to $1.1 billion in 2022, then grew by 12.8% to $1.2 billion in 2023, then skyrocketed by 64.99% to $2.0 billion in 2024, then soared by 46.27% to $3.0 billion in 2025.
  • Its EBIT was $3.0 billion in Q4 2025, compared to $3.6 billion in Q3 2025 and $3.5 billion in Q2 2025.